Companies Dominating the Opioid Antagonist Landscape
- Indivior PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- •Regional Presence
- SWOT Analysis
- Alkermes.
- Titan Pharmaceuticals, Inc.
- Hikma Pharmaceuticals PLC
- Orexo AB
- Camurus AB
- Acura Pharmaceuticals.
- Collegium Pharmaceutical
- AstraZeneca
- Viatris Inc.
- Catalent, Inc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of opioid antagonist is estimated at USD 3.69 billion.
The opioid antagonist market size was valued at USD 3.34 billion in 2024 and is set to exceed USD 15.44 billion by 2037, registering over 12.5% CAGR during the forecast period i.e., between 2025-2037. Increased investments in healthcare, rising awareness, and increase in public health initiatives will boost the market growth.
North America industry is likely to dominate majority revenue share of 38% by 2037, due to high prevalence of opioid addiction and overdose deaths has prompted regulatory bodies to streamline approval processes for opioid antagonists, fostering a competitive market in the region.
The major players in the market are Merck & Co., Inc., Siemens Healthcare GmbH, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Valenta Pharmaceuticals Company, Novartis AG, Sanofi-Aventis Groupe, AbbVie Inc., Elli Lilly and Company, and others.
